NCT02981940View on ClinicalTrials.gov

A Study of Abemaciclib in Recurrent Glioblastoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 9, 2017

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2026

Conditions
Glioblastoma
Interventions
DRUG

Abemaciclib

Abemaciclib capsule

PROCEDURE

Surgery

Surgery

Trial Locations (7)

10021

Memorial Sloan-Kettering Cancer Center, New York

77030

UT, M.D. Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute, Salt Lake City

90095

University of California Los Angeles, Los Angeles

94143-0372

University of California, San Francisco, San Francisco

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER